Natixis decreased its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 40.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,789 shares of the biotechnology company’s stock after selling 48,906 shares during the period. Natixis’ holdings in Cerevel Therapeutics were worth $3,035,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Headlands Technologies LLC purchased a new stake in shares of Cerevel Therapeutics in the first quarter valued at approximately $26,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $71,000. Centaurus Financial Inc. purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $119,000. GAM Holding AG purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $212,000. Finally, Virtu Financial LLC purchased a new stake in Cerevel Therapeutics during the fourth quarter worth $246,000. Hedge funds and other institutional investors own 87.73% of the company’s stock.
Insiders Place Their Bets
In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the completion of the sale, the director now owns 25,928 shares in the company, valued at $1,067,715.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 5.10% of the stock is owned by company insiders.
Cerevel Therapeutics Price Performance
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, research analysts forecast that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current fiscal year.
Cerevel Therapeutics Company Profile
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Further Reading
- Five stocks we like better than Cerevel Therapeutics
- Investing In Preferred Stock vs. Common Stock
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Sentiment Analysis: How it Works
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- The 3 Best Blue-Chip Stocks to Buy Now
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding CERE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report).
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.